Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Éva DókaDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, 1122 Budapest, Hungary.ORCID 0000-0002-7966-2431
Elias S J ArnérDepartment of Selenoprotein Research, National Institute of Oncology, 1122 Budapest, Hungary.ORCID 0000-0002-4807-6114
Edward E SchmidtDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.ORCID 0000-0002-9959-4990
Tobias P DickDivision of Redox Regulation, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.ORCID 0000-0003-1367-973X
Albert van der VlietDepartment of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT 05405, USA.ORCID 0000-0003-0923-0016
Jing YangState Key Laboratory of Proteomics, National Center for Protein Sciences, Beijing Proteome Research Center, Beijing Institute of Lifeomics, 102206 Beijing, China.ORCID 0000-0001-8486-273X
Réka SzatmáriDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, 1122 Budapest, Hungary.
Tamás DitróiDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, 1122 Budapest, Hungary.
John L WallaceDepartment of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4N1, Canada.
Giuseppe CirinoDepartment of Pharmacy, University of Naples Federico II, Naples 80138, Italy.ORCID 0000-0003-3954-4083
Kenneth OlsonDepartment of Physiology, Indiana University School of Medicine-South Bend, South Bend, IN 46617, USA.ORCID 0000-0003-0178-2203
Hozumi MotohashiDepartment of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, 980-8575 Sendai, Japan.ORCID 0000-0002-7261-1033
Jon M FukutoDepartment of Chemistry, Sonoma State University, Rohnert Park, Sonoma, CA 94928, USA.
Michael D PluthDepartment of Chemistry and Biochemistry, Materials Science Institute, Institute of Molecular Biology, University of Oregon, Eugene, OR 97403, USA.ORCID 0000-0003-3604-653X
Martin FeelischClinical and Experimental Sciences, Faculty of Medicine, and University Hospital Southampton NHS Foundation Trust, University of Southampton, SO16 6YD Southampton, UK.ORCID 0000-0003-2320-1158
Takaaki AkaikeDepartment of Environmental Medicine and Molecular Toxicology, Tohoku University Graduate School of Medicine, 980-8575 Sendai, Japan.ORCID 0000-0002-0623-1710
David A WinkChemical and Molecular Inflammation Section, Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA.
Louis J IgnarroUniversity of California, Los Angeles School of Medicine, Beverly Hills, CA 90212, USA.
Péter NagyDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, 1122 Budapest, Hungary. peter.nagy@oncol.hu.ORCID 0000-0003-3393-235X
Funding
Nitric Oxide as a Modifier of Oxidative StressZIASC007281 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WINK, DAVID · 2009 to 2025
$8.1M
Properties of redox modified NSAIDs in cancer prevention and treatmentZIABC010899 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINK, DAVID · 2009 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comment on "Evidence that the ProPerDP method is inadequate for protein persulfidation detection due to lack of specificity". · full record | OpenQuestion